INKT (MiNK Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


INKT MiNK Therapeutics Inc INKT
34 GF Score
Price $11.41
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics FCF Margin %?

MiNK Therapeutics INKT +2.56% 34 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates INKT with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, MiNK Therapeutics ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MiNK Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-1.73 Mil. MiNK Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, MiNK Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, MiNK Therapeutics's current FCF Yield % is -11.11%.

The historical rank and industry rank for MiNK Therapeutics's FCF Margin % or its related term are showing as below:


During the past 7 years, the highest FCF Margin % of MiNK Therapeutics was -2227.54%. The lowest was -2227.54%. And the median was -2227.54%.

INKT's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

MiNK Therapeutics FCF Margin % Related Terms

MiNK Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics FCF Margin % Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

INKT vs PDSB, PMVP, EDSA: FCF Margin % Comparison

For the Biotechnology subindustry, MiNK Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiNK Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's FCF Margin % falls into.


INKT
34GF Score
MiNK Therapeutics Inc INKT
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MiNK Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-5.925/0
= %

MiNK Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-1.733/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
MiNK Therapeutics (INKT) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MiNK Therapeutics and its competitors. According to the industry distribution chart, MiNK Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry.
Is MiNK Therapeutics' FCF Margin % too high?
MiNK Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, MiNK Therapeutics ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MiNK Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' FCF Margin % compare to PDSB and PMVP?
According to the Biotechnology industry distribution chart, MiNK Therapeutics ranks #999999 out of 959 companies for FCF Margin %. This places MiNK Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. MiNK Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
34GF Score

Get the complete analysis for INKT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.41
Price